

SUPPLEMENTAL MATERIAL

Targeting xenobiotic nuclear receptors PXR and CAR to prevent cobicistat hepatotoxicity

Amina I. Shehu¹, Junjie Zhu¹, Jianhua Li¹, Jie Lu¹, Deborah McMahon², Wen Xie¹,

Frank J. Gonzalez³, Xiaochao Ma¹


Supplemental Fig. 1. Deficiency of PXR or CYP3A4 protects against liver injury caused by the adverse drug-drug interactions between RIF and COBI.

Supplemental Fig. 2. Pretreatment with RIF accelerates COBI metabolism in the liver microsomes of hPXR/CYP3A4 mice.

Supplemental Fig. 3. The adverse drug-drug interactions between RIF and COBI cause oxidative stress in the liver in a PXR- and CYP3A4-dependent manner.


Supplemental Fig. 4. CDDO-Im, an antioxidant, prevents liver injury caused by the adverse drug-drug interactions between RIF and COBI in hPXR/CYP3A4 mice.

Supplemental Fig. 1



Supplemental Fig. 1. Deficiency of PXR or CYP3A4 protects against liver injury caused by the adverse drug-drug interactions between RIF and COBI. Pxr-null/CYP3A4 and hPXR/Cyp3a-null mice were pretreated with RIF for 7 days followed by COBI for 1 day. No injury was observed in histological analysis of livers from control (A, C) and RIF+COBI (B, D) groups. H&E staining. CV, central vein. Scale bars: 50 μ m.


Supplemental Fig. 2



Supplemental Fig. 2. Pretreatment with RIF accelerates COBI metabolism in the liver


microsomes of hPXR/CYP3A4 mice. The incubation was carried out in 1 x PBS containing 30 μ M of COBI and 1 mg of liver microsomes for 30 min. The remaining COBI in the incubation system was analyzed by UPLC-qTOFMS. All data are expressed as mean \pm SD (n = 3-4). Data in control groups are set as 1, respectively. *** $P < 0.001$.

Supplemental Fig. 3



Supplemental Fig. 3. The adverse drug-drug interactions between RIF and COBI cause oxidative stress in the liver in a PXR- and CYP3A4-dependent manner. hPXR/CYP3A4, Pxr-null/CYP3A4, and hPXR/Cyp3a-null mice were pretreated with RIF followed by COBI. *Gpx3* (A), *Gpx4* (B), *Slc7a11* (C), and *Slc25a24* (D) mRNAs in the liver were analyzed by qPCR. All data are expressed as mean \pm SEM (n = 3-7). Data in control groups are set as 1, respectively. Statistical significance was determined by two-way ANOVA with Tukey's post hoc test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

Supplemental Fig. 4



Supplemental Fig. 4. CDDO-Im, an antioxidant, prevents liver injury caused by the adverse drug-drug interactions between RIF and COBI in hPXR/CYP3A4 mice. The mice were pretreated with RIF and antioxidant CDDO-Im followed by COBI. **(A)** The levels of ophthalmic acid (OA), a biomarker of oxidative stress, in the liver of hPXR/CYP3A4 mice pretreated with RIF followed by COBI. **(B)** Impact of CDDO-Im on RIF-mediated CYP3A4 induction in the liver of hPXR/CYP3A4 mice. CYP3A4 was analyzed by Western blotting. Gapdh was used as a loading control. **(C)** The effects of CDDO-Im on OA levels in the liver of hPXR/CYP3A4 mice pretreated with RIF followed by COBI. OA in the liver was analyzed by UPLC-qTOFMS. **(D, E)** The effects of CDDO-Im on the liver injury in hPXR/CYP3A4 mice

pretreated with RIF followed by COBI. Serum activities of ALT (**D**) and AST (**E**) were analyzed by a biochemical approach. All data are expressed as mean \pm SEM (n = 3-7). Statistical significance was determined by the two-tailed Student's t-test. * $P < 0.05$, ** $P < 0.01$.